Therapeutic strategies targeting APOE4, such as angiotensin receptor blockers, vascular endothelial growth factor A (VEGFA), and epidermal growth factor (EGF), can potentially improve BBB integrity and function and slow AD progression [98]. Here, VEGFA is linked to Alzheimer disease.